Skip to main content

Table 1 Baseline characteristics of patientsa with and without day 7 lumefantrine concentrations

From: Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data

Parameter Patients with day 7 lumefantrine concentration Patients without day 7 lumefantrine concentration P valueb
  N Median (range) or N (%) N Median (range) or N (%)  
Age (years) 2,786 6.2 (0.3 to 86.7) 2,805 5.5 (0.2 to 80.0) 0.028
Age category      <0.001
  < 1 year   82 (3.0)   107 (3.8)
 1–2 years   573 (20.6)   590 (21.0)
 3–4 years   615 (22.1)   604 (21.5)
 5–11 years   564 (20.2)   852 (30.4)
  ≥ 12 years   953 (34.2)   652 (23.2)
Weight (kg) 2,786 18.5 (5.0 to 150.0) 2,797 17.0 (5.0 to 97.0) 0.104
Underweightc 1,269 220 (17.3) 1,299 218 (16.8) 0.211
Total dose (mg/kg) 2,764 65.5 (19.2 to 144.0) 2,786 65.5 (20.9 to 144) 0.092
Treatment supervision 2,787   2,788   <0.001
 Fully 1,971 (70.7) 1,644 (59.0)
 Partially 115 (4.1) 602 (21.6)
 Unsupervised 701 (25.2) 542 (19.4)
Co-administration with fat 2,787   2,809   0.147
Yes/advised 2,204 (79.1) 1,752 (62.4)
Not stated 583 (20.9) 1,057 (37.6)
Parasitemia (/μl) 2,767 17,140 (16 to 524,414) 2,799 18,120 (10 to 862,400) 0.021
Temperature (°C) 2,662 37.7 (34.3 to 41.9) 1,967 37.5 (35.0 to 41.5) <0.001
Hemoglobin (g/dL) 2,068 10.6 (4.8 to 25) 1,484 11.3 (4.2 to 17.9) 0.428
Sex (female) 2,787 1,281 (46.0) 2,805 1,278 (45.6) 0.857
Gametocytes present 2,418 112 (4.9) 1,654 92 (5.6) 0.797
Moderate anemia 2,507 1,132 (45.1) 1,484 516 (34.8) 0.016
Severe anemia 2,507 155 (6.2) 1,484 57 (3.8) 0.056
  1. aPatients enrolled in the 21 studies included in the pooled analysis; badjusted for study site in a random effects model; cdefined using a weight-for-age Z-score (WAZ) < −2 in children <5 years of age